Mini-reviewAllosteric modulation of G-protein coupled receptors
Introduction
Cell surface receptors are membrane bound proteins that translate extracellular signals delivered as neurotransmitters or hormones into intracellular cascades and events such as phosphorylation, calcium mobilisation and opening of ion channels. The three major classes of cell surface receptors are ligand-gated ion channels, tyrosine kinase receptors and G-protein coupled receptors (GPCRs). These receptor classes constitute the majority of the therapeutic targets identified today, with drugs targeted to GPCRs accounting for $18,548 million in sales during 2000 (Bailey, 2001).
GPCR ligands generally act by stimulating a response (agonists) or blocking the activity of an endogenous agonist (competitive antagonists). Inverse agonists also block the constitutive activity of a GPCR. Since most ligands appear unable to bind simultaneously with each other (e.g. in radioligand binding), and are similarly affected by mutations in the receptors, it is generally assumed that they act through the binding site of endogenous transmitter at the receptor, the orthosteric site.
In recent years, there has been increasing therapeutic interest in ligands that bind to other sites on the receptor, allosteric sites. Many allosteric modulators have little or no agonist or inverse agonist activity themselves, but they affect the receptor’s response to endogenous agonists and other ligands. Classical examples of allosteric modulators include benzodiazepines and barbiturates, which enhance or inhibit GABAA receptor function, and memantine which negatively modulates NMDA receptors (Kohl and Dannhardt, 2001, Mohler et al., 2002). These receptors are ion channels. In contrast, the vast majority of clinically-used GPCR ligands are believed to act orthosterically. Recently, rapid developments in combinatorial chemistry and high throughput screening techniques have helped identify numerous allosteric ligands, several of which already have become valuable pharmacological tools and may be candidates for clinical testing in the near future.
In this review, we discuss the pharmacological characteristics of allosteric modulators, the interactions of specific allosteric modulators with their respective GPCRs, and the potential therapeutic advantages of allosteric versus orthosteric ligands.
Section snippets
GPCR function and allosteric modulation
The term “GPCR” originates from these receptors’ ability to associate with heterotrimeric G-proteins and through them stimulate or inhibit the formation of second messengers such as inositol-3,4,5-tris-phosphate and cyclic AMP and modulate the function of ion channels (Gether, 2000, Pierce et al., 2002). They are also capable of interacting directly with ion channels and other effector molecules (Pierce et al., 2002). The GPCRs do not share an overall amino acid sequence identity and as shown
Endogenous GPCR modulators
The modulation of GPCRs by endogenous substrates could be perceived as one of nature’s subtle ways of fine-tuning neurotransmitter/hormone signalling. A classic case of endogenous GPCR modulation is the electrostatic interaction between a sodium ion and a highly conserved aspartate residue located in cytoplasmic part of TM2 of a number of family A GPCRs (Fig. 4) (Horstman et al., 1990, Neve et al., 1991, Neve et al., 2001, Martin et al., 1999, Schetz and Sibley, 2001, Gao et al., 2003).
GPCRs, GPCR dimers and GPCR-protein complexes as targets for allosteric modulators
It is clear that GPCRs can be activated by mechanisms that do not involve agonist binding to the orthosteric ligand binding site. Schwartz and coworkers have engineered artificial agonistic Zn2+ binding sites in analogous positions in the β2-adrenergic receptor and the distantly related tachykinin NK1 receptor (Elling et al., 1999, Holst et al., 2000). This is remarkable considering the different binding modes of the orthosteric ligands to the two receptors (Fig. 1). Furthermore, there are
Nature of response
Allosteric modulators with little inherent intrinsic activity that act by enhancing or attenuating the response elicited by the endogenous transmitter hold several advantages to the actions of conventional agonists and antagonists. Firstly, the effects of the allosteric modulator are often saturable and are therefore less likely to elicit adverse effects from overdose. Secondly, the effects of the modulator are closely linked with the physiological pulse of synaptic signalling, and thus it will
Conclusion
Increasing numbers of allosteric GPCR ligands are being published. Subtype-selective allosteric ligands have already proven valuable pharmacological tools in in vivo investigations of the physiological roles of GPCRs, and delineation of the interactions of these ligands with their respective receptors have contributed significantly to the understanding of the signal transduction through the receptors. Considering the continued extensive use of high throughput technologies in the drug discovery
Acknowledgements
The Lundbeck Foundation is thanked for its financial support of AAJ.
References (107)
- et al.
Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes
Life Sci.
(1997) Neurobiology of zinc and zinc-containing neurons
Int. Rev. Neurobiol.
(1989)- et al.
G protein antagonists
Trends Pharmacol. Sci.
(1999) - et al.
Allosteric modulation of A2A adenosine receptors by amiloride analogues and sodium ions
Biochem. Pharmacol.
(2000) - et al.
Metal-ion mediated agonism and agonist-enhancement in the melanocortin MC1 and MC4 receptors
J. Biol. Chem.
(2002) - et al.
An aspartate conserved among G-protein receptors confers allosteric regulation of α2-adrenergic receptors by sodium
J. Biol. Chem.
(1990) - et al.
The dance of the clams: twists and turns in the family C GPCR homodimer
Trends Pharmacol. Sci.
(2002) Ligand-selective receptor conformations revisited: the promise and the problem
Trends Pharmacol. Sci.
(2003)The two-state model of receptor activation
Trends Pharmacol. Sci.
(1995)- et al.
Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes
J. Biol. Chem.
(2003)
Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis ammonium compounds
Eur. J. Pharmacol.
(−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection
Neuropharmacology
Reassessment of the Ca2+ sensing property of a type I metabotropic glutamate receptor by simultaneous measurement of inositol 1,4,5-trisphosphate and Ca2+ in single cells
J. Biol. Chem.
The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states
J. Biol. Chem.
A model for the functioning of family 3 GPCRs
Trends Pharmacol. Sci.
Natural agonist enhancing bis-His zinc-site in transmembrane segment V of the tachykinin NK3 receptor
FEBS Lett.
A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry
J. Biol. Chem.
Identification of allosteric peptide agonists of CXCR4
J. Biol. Chem.
A mutation-induced activated state of the β2-adrenergic receptor
J. Biol. Chem.
Allosteric α1-adrenoceptor antagonism by the conopeptide ρ-TIA
J. Biol. Chem.
Identification of a ligand-dependent switch within a muscarinic receptor
J. Biol. Chem.
Allosteric modulation of muscarinic acetylcholine receptors
Trends Pharmacol. Sci.
Allosteric modulation of the human 5-HT7A receptor by lipidic amphipathic compounds
Mol. Pharmacol.
Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function
Annu. Rev. Pharmacol. Toxicol.
Subtype-selective positive co-operative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies
Mol. Pharmacol.
Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands
Mol. Pharmacol.
BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity
Mol. Pharmacol.
G protein-coupled receptor allosterism and complexing
Pharmacol. Rev.
The inhibitory effect of gallamine on muscarinic receptors
Br. J. Pharmacol.
L-amino acid sensing by the extracellular Ca2+-sensing receptor
Proc. Natl. Acad. Sci. U.S.A.
Antagonists with negative intrinsic activity at d opioid receptors coupled to GTP-binding proteins
Proc. Natl. Acad. Sci. U.S.A.
G-protein-coupled receptors for neurotransmitter amino acids: C-terminal tails, crowded signalosomes
Biochem. J.
Conversion of agonist site to metal-ion chelator site in the β2-adrenergic receptor
Proc. Natl. Acad. Sci. U.S.A.
Two allosteric modulators interact at a common site on cardiac muscarinic receptors
Mol. Pharmacol.
Interactions of alcuronium, TMB-8, and other allosteric ligands with muscarinic acetylcholine receptors: studies with chimeric receptors
Mol. Pharmacol.
Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions
Mol. Pharmacol.
SCH-202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors
Mol. Pharmacol.
A new peptide, 5-HT-moduline, isolated and purified from mammalian brain specifically interacts with 5-HT1B/1D receptors
Behav. Brain Res.
Allosteric modulation of A3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives
Mol. Pharmacol.
Identification of essential residues involved in the allosteric modulation of the human A3 adenosine receptor
Mol. Pharmacol.
Uncovering molecular mechanisms involved in activation of G protein-coupled receptors
Endocr. Rev.
Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors
Mol. Pharmacol.
Modelling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation
Mol. Pharmacol.
Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568
Mol. Pharmacol.
Domains determing ligand specificity for Ca2+ receptors
Mol. Pharmacol.
The regulation of D2 dopamine receptors by amiloride and amiloride analogues
Mol. Pharmacol.
Gsα-selective G protein antagonists
Proc. Natl. Acad. Sci. U.S.A.
Partial agonism through a zinc-ion switch constructed between transmembrane domains III and VII in the tachykinin NK1 receptor
Mol. Pharmacol.
Cited by (105)
Manganese toxicity is targeting an early step in the dopamine signal transduction pathway that controls lateral cilia activity in the bivalve mollusc Crassostrea virginica
2018, Comparative Biochemistry and Physiology Part - C: Toxicology and PharmacologyCitation Excerpt :G protein coupled metabotropic receptors have been shown susceptible to allosteric inhibition by metals. Zinc is well known to modulate ligand binding and affect the functional properties of a wide range of GPCR (Jensen and Spalding, 2004) including 5 HT1A (Barrondo and Salles, 2009), β2 adrenergic (Swaminath et al., 2002, 2003), μ-opioid (Fowler et al., 2004) and D1DR (Schetz and Sibley, 1997). Specifically for D2R, Liu et al. (2006) identified the presence of zinc binding sites that contribute to allosteric regulation of ligand binding (Schetz and Sibley, 1997).
New effects of GABA<inf>B</inf> receptor allosteric modulator rac-BHFF on ambient GABA, uptake/release, Em and synaptic vesicle acidification in nerve terminals
2015, NeuroscienceCitation Excerpt :Allosteric modulators bind not to the orthosteric site of endogenous-ligand interaction, but act by enhancing or attenuating the response evoked by the endogenous transmitter or agonist (Jensen and Spalding, 2004; Conn et al., 2009; Hensler et al., 2012). Allosteric modulators alter the effects of activated receptors without affecting nonactivated receptors, and so they may have a broader therapeutic window than transmitters and agonists (Jensen and Spalding, 2004; Pin and Prézeau, 2007; Conn et al., 2009). GABAB receptor-positive modulators are thought to have advantages as potential medications for anxiety, depression, and drug addiction, because they may have a better side-effect profile than GABAB receptor agonists (Koek et al., 2013).
Neuroprotective mode of action of resveratrol in central nervous system
2013, PharmaNutritionInvestigation of Lactone Chiral Enantiomers and Their Contribution to the Aroma of Longjing Tea by Odor Activity Value and S-Curve
2023, Journal of Agricultural and Food Chemistry